Molecular Mechanism Found to Combat Leukemia Stem Cells
Researchers have discovered that targeting the NYNRIN protein can effectively trigger apoptosis in leukemia stem cells.
Updated on Oct. 25, 2026 in Cancer
Scientists have identified that the protein NYNRIN plays a critical role in maintaining the survival of leukemia stem cells by regulating redox homeostasis. Inhibiting this protein destabilizes the cells and increases their sensitivity to existing treatments like venetoclax.
Why it matters
High levels of NYNRIN correlate with poor patient prognosis, making it a significant potential target for improving acute myeloid leukemia therapies. By disabling this molecular safeguard, researchers can lower the apoptotic threshold of cancerous stem cells.
Researchers observed that NYNRIN functions by binding and degrading TXNIP mRNA, a process that sustains thioredoxin-mediated redox buffering. Inhibiting NYNRIN triggers TXNIP accumulation and elevates reactive oxygen species within leukemia stem cells.
The details
The NYNRIN protein acts as an RNA-binding protein that utilizes its NYN domain to prevent TXNIP accumulation. When this process is blocked, the resulting oxidative stress forces the leukemia stem cells into apoptosis, effectively rendering them more vulnerable to venetoclax.
Timeline
The research findings were officially published on October 25, 2026.
The Big Picture
This research advances the clinical application of venetoclax by identifying a specific molecular pathway to overcome stem cell resistance. By disrupting redox homeostasis, the findings suggest a paradigm shift in how clinicians might address therapy-resistant leukemia stem cell populations.
While this discovery is currently limited to laboratory research, it provides a foundation for developing future therapies that could increase treatment efficacy for leukemia patients. These insights may eventually lead to new drug combinations that lower the risk of cancer relapse.
The takeaway
Understanding the role of NYNRIN offers a promising target for neutralizing the protective mechanisms that allow leukemia stem cells to persist. Patients and families should track future updates on therapeutic inhibitors that capitalize on this redox-balancing vulnerability.
Further reading
For more information on current treatment landscapes, visit the Cancer section.
More information
Read the complete findings in the Nature research article.
